<DOC>
	<DOCNO>NCT00216879</DOCNO>
	<brief_summary>The purpose trial study safety efficacy long term use daily application , need , calcipotriol plus betamethasone dipropionate gel , compare calcipotriol alone gel . The primary response criterion incidence adverse drug reaction type , incidence adverse event concern associate long-term corticosteroid use scalp .</brief_summary>
	<brief_title>Efficacy Safety Calcipotriol Plus Betamethasone Dipropionate Gel Year Scalp Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Scalp psoriasis amenable topical treatment maximum 100 g study medication per week Clinical sign psoriasis vulgaris trunk and/or limb , early diagnose psoriasis vulgaris trunk and/or limbs Extent scalp psoriasis involve 10 % total scalp area Disease severity scalp grade Moderate , Severe Very Severe accord Investigator 's Global Assessment disease severity PUVA Grenz ray therapy anywhere patient within 28 day prior randomisation UVB therapy anywhere patient within 14 day prior randomisation Systemic use biological treatment , whether market , direct potential effect , scalp psoriasis ( e.g. , alefacept , efalizumab , etanercept , infliximab ) within 6 month prior randomisaiton Systemic treatment potential effect scalp psoriasis vulgaris ( e.g. , corticosteroid , retinoids , immunosuppressant ) within 28 day prior randomisation Any topical treatment scalp psoriasis skin disease scalp ( exclude medicate shampoo , emollient hair conditioner ) within 14 day prior randomisaiton Topical treatment skin disorder potent WHO group IV corticosteroid within 14 day prior randomisation Planned initiation , change dose concomitant medication could affect scalp psoriasis ( e.g. , beta blocker , antimalarial drug , lithium ) study Current diagnosis guttate , pustular , exfoliative erythrodermic psoriasis Patients follow condition present scalp area : viral lesion , fungal bacterial skin infection , parasitic infection atrophic skin Known suspect severe renal insufficiency severe hepatic disorder Patiens history/signs/symptoms suggestive abnormality calcium homeostasis associate clinically significant hypercalcaemia Trial subject use adequate method contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>